Expression and Clinical Significance of miRNA-152 in Hepatocellular Carcinoma

PENG Qiliu; WEI Shangmou; ZHANG Lei; GAN Liying; XIE Zhen; CHEN Qiaopei; WEI Bangning; ZHANG Zhi

doi:10.3971/j.issn.1000-8578.2021.21.0296

Cancer Research on Prevention and Treatment > 2021 > 48(8): 769-773. > DOI: 10.3971/j.issn.1000-8578.2021.21.0296

PENG Qiliu, WEI Shangmou, ZHANG Lei, GAN Liying, XIE Zhen, CHEN Qiaopei, WEI Bangning, ZHANG Zhi. Expression and Clinical Significance of miRNA-152 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 769-773. DOI: 10.3971/j.issn.1000-8578.2021.21.0296

Citation:

PDF (2995 KB)

Expression and Clinical Significance of miRNA-152 in Hepatocellular Carcinoma

1.
Department of Clinical Laboratory, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China
2.
Department of Clinical Laboratory, Maternity and Child Health Care of Guangxi Zhuang Autonomous Region, Nanning 530021, China
3.
Department of Hepatobiliary Surgery, Guangxi International Zhuang Medicine Hospital, Nanning 530201, China
4.
Department of Hepatobiliary Surgery, The First People's Hospital of Nanning, Nanning 530022, China

Funding:

Natural Science Foundation of Guangxi 2017JJA10583

Science and Technology Development Program of Nanning City 20163126

2019 Doctoral Research Fund of Guangxi University of Chinese Medicine 2019BS042

More Information

Corresponding author:
CHEN Qiaopei, E-mail: chenqiaopei@163.com
Received Date: March 16, 2021
Revised Date: May 09, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the expression of microRNA-152 in hepatocellular carcinoma, and analyze the correlation of miR-152 expression with the clinicopathological characteristics of hepatocellular carcinoma(HCC) patients.
Methods
Real-time PCR was used to detect the expression of miR-152 in tissue specimens from HCC and the adjacent non-cancerous hepatic tissues collected from 56 patients who underwent surgical treatment for primary HCC. The association between the expression of miR-152 and the clinical pathological characteristics and prognosis of HCC patients was analyzed.
Results
The relative expression of miR-152 in hepatocellular carcinoma and corresponding adjacent non-carcinoma tissues were 0.616±0.041 and 0.768±0.042 (P=0.011). The expression of miR-152 was significantly associated with TNM stages (P=0.042), tumor differentiation (P=0.035), metastasis (P=0.048) and venous invasion (P=0.042). There was no significant association between the miR-152 expression and gender, age, AFP level, tumor number or tumor grade. The OS (P=0.035) and PFS (P=0.012) in the low miR-152 expression group were obviously shorter than those in the high miR-152 expression group. Multivariate Cox regression analysis showed that the low expression of miR-152, tumor recurrence and pathological classification were significant independent prognostic factors for the prognosis of hepatocellular carcinoma patients.
Conclusion
The expression of miR-152 is decreased in hepatocellular carcinoma tissues, and the low expression of miR-152 is significantly associated with TNM stages, tumor differentiation, metastasis, venous invasion and the prognosis of HCC patients.
- Hepatocellular carcinoma,
- MicroRNA-152,
- Overall survival,
- Prognosis

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (18)

References

[1]	Komoll RM, Hu Q, Olarewaju O, et al. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma[J]. J Hepatology, 2021, 74(1): 122-134. doi: 10.1016/j.jhep.2020.07.039
[2]	Wu J, Xie N, Xie K, et al. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer[J]. Carcinogenesis, 2013, 34(12): 2861-2869. doi: 10.1093/carcin/bgt229
[3]	李自慧, 叶甲舟, 陈洁, 等. 解剖性肝切除术对合并微血管侵犯的肝癌患者早期复发的影响[J]. 中华肝胆外科杂志, 2018, 24(1): 18-22. doi: 10.3760/cma.j.issn.1007-8118.2018.01.005 Li ZH, Ye JZ, Chen J, et al. The impact of anatomical resection for hepatocellular carcinoma with microvascular invasion on early tumor recurrence[J]. Zhonghua Gan Dan Wai Ke Za Zhi, 2018, 24(1): 18-22. doi: 10.3760/cma.j.issn.1007-8118.2018.01.005
[4]	Brennan GP, Henshall DC. MicroRNAs as regulators of brain function and targets for treatment of epilepsy[J]. Nat Rev Neurol, 2020, 16(9): 506-519. doi: 10.1038/s41582-020-0369-8
[5]	Wei L, Wang X, Lv L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma[J]. Mol Cancer, 2019, 18(1): 147. doi: 10.1186/s12943-019-1086-z
[6]	Yang C, Zheng X, Ye K, et al. miR-135a Inhibits the Invasion and Migration of Esophageal Cancer Stem Cells through the Hedgehog Signaling Pathway by Targeting Smo[J]. Mol Ther Nucleic Acids, 2020, 19: 841-852. doi: 10.1016/j.omtn.2019.10.037
[7]	Rezaei T, Amini M, Hashemi ZS, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers[J]. Free Radic Biol Med, 2020, 152: 432-454. doi: 10.1016/j.freeradbiomed.2019.12.043
[8]	Weng J, Luo J, Cheng X, et al. Deletion of G protein-coupled receptor 48 leads to ocular anterior segment dysgenesis (ASD) through down-regulation of Pitx2[J]. Proc Natl Acad Sci USA, 2008, 105(16): 6081-6086. doi: 10.1073/pnas.0708257105
[9]	Shen K, Cao Z, Zhu R, et al. The dual functional role of MicroRNA-18a (miR-18a) in cancer development[J]. Clin Transl Med, 2019, 8(1): 32. doi: 10.1186/s40169-019-0250-9
[10]	Li B, Xie Z, Li B. miR-152 functions as a tumor suppressor in colorectal cancer by targeting PIK3R3[J]. Tumour Biol, 2016, 37(8): 10075-10084. doi: 10.1007/s13277-016-4888-2
[11]	Liu Y, Gao S, Du Q, et al. miR-146a and miR-152 in prostate cancer and clinicopathological parameters[J]. J BUON, 2019, 24(4): 1692-1699. http://www.researchgate.net/publication/336824331_miR-146a_and_miR-152_in_prostate_cancer_and_clinicopathological_parameters/download
[12]	Ghazanchaei A, Mansoori B, Mohammadi A, et al. Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer[J]. J Cell Physiol, 2018, 234(1): 769-776. http://www.ncbi.nlm.nih.gov/pubmed/30076720
[13]	Yang D, Zhang Q. miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer[J]. Oncol Lett, 2019, 17(6): 5693-5698. http://www.ingentaconnect.com/content/sp/ol/2019/00000017/00000006/art00116
[14]	汪毅, 袁伟, 马肖, 等. miR-152在结直肠癌组织中的表达及其与预后的关系[J]. 中华肿瘤杂志, 2016, 38(10): 763-766. doi: 10.3760/cma.j.issn.0253-3766.2016.10.010 Wang Y, Yuan W, Ma X, et al. Expression of microRNA-152 in colorectal cancer and its relationship with prognosis[J]. Zhonghua Zhong Liu Za Zhi, 2016, 38(10): 763-766. doi: 10.3760/cma.j.issn.0253-3766.2016.10.010
[15]	张红森, 郭国营, 杨翠, 等. MiR-152在膀胱癌中的表达以及对ERBB3/AKT2信号通路的调节作用[J]. 中国肿瘤, 2019, 28(1): 55-62. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201901009.htm Zhang HS, Guo GY, Yang C, et al. Expression of MiR-152 in Bladder Cancer and Its Effect on ERBB3/Akt Signal Pathway[J]. Zhongguo Zhong Liu, 2019, 28(1): 55-62. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201901009.htm
[16]	Wang F, Ying H, He B, et al. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma[J]. Tumour Biol, 2016, 37(4): 4945-4953. doi: 10.1007/s13277-015-4340-z
[17]	Dang YW, Zeng J, He RQ, et al. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells[J]. Asian Pac J Cancer Prev, 2014, 15(12): 4969-4976. doi: 10.7314/APJCP.2014.15.12.4969
[18]	Yin T, Liu MM, Jin RT, et al. miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8[J]. Pathol Res Pract, 2019, 215(6): 152406. doi: 10.1016/j.prp.2019.03.034

[1]	WU Yang, LI Tian, SHI Tingting, ZHU Lingling, ZHANG Yani, GUO Peipei, ZHANG Runbing, WANG Shunna, GAO Chun, YU Xiaohui, ZHANG Jiucong. Influencing Factors of Overall Survival of Elderly Patients with Hepatocellular Carcinoma and Construction of Prediction Model of Prognosis Nomogram: A Population-Based Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 756-763. DOI: 10.3971/j.issn.1000-8578.2024.24.0009
[2]	ZHOU Sicheng, WU Haifeng, PAN Yuting, YUN Hong, CAO Shaomu, NIE Hongxia, XING Wei, LIANG Jianwei. Clinicopathological Characteristics and Survival Prognosis Analysis of 102 Rectal Cancer Patients with Lateral Pelvic Lymph Node Metastases[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 33-37. DOI: 10.3971/j.issn.1000-8578.2023.22.0655
[3]	YANG Qian, YE Dongxue, MA Yanran, HU Xiaoyuan, LI Hong, ZHOU Xuan, XIANG Fenggang. EIF5A2 Expression in Hepatocellular Carcinoma and Its Relation with Postoperative Survival[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 617-624. DOI: 10.3971/j.issn.1000-8578.2021.20.1437
[4]	ZHENG Lihua, LIU Feng, LI Wei, ZHAO Yaheng, YANG Yan, WU Shang, LIU Yunjiang. Relation Between Albumin to Fibrinogen Ratio and Overall Survival of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 102-107. DOI: 10.3971/j.issn.1000-8578.2020.19.0684
[5]	ZHANG Qiuming, ZHONG Jianhong, YOU Xuemei, MA Liang, XIANG Bangde, ZHU Shaoliang, GONG Wenfeng, LI Lequn. Prognosis of HBV-related Hepatocellular Carcinoma Patients Treated with Nucleos(t)ide Analogue Therapy Combined with Transarterial Chemoembolization[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 792-795. DOI: 10.3971/j.issn.1000-8578.2016.09.013
[6]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[7]	MAO Zhiyuan, XIONG Mei, REN Li, LI Dechang, YUE Ying, ZHENG Jichun. Pathological Factors for Prognosis of Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 777-780. DOI: 10.3971/j.issn.1000-8578.2014.07.019
[8]	HE Yong, LI Tao-Yuan, DIAO Li. Peripheral Blood Cell Analyze and Their Relationship with Prognosis of Advanced NSCLC Patients[J]. Cancer Research on Prevention and Treatment, 2006, 33(08): 588-590. DOI: 10.3971/j.issn.1000-8578.1823
[9]	XU Hong, WANG ZHong-mi. A clinical analysis and prognosis of 38 uterine sarcoma[J]. Cancer Research on Prevention and Treatment, 2002, 29(06): 487-488. DOI: 10.3971/j.issn.1000-8578.2455
[10]	Wang YanYing, . Pathological Analysis in the Relation with the Expression ER and PR and the Prognosis on the Rectal cancernoma[J]. Cancer Research on Prevention and Treatment, 1996, 23(1): 30-31.

Cited By

Cited by

Periodical cited type(4)

1.	底静，白雪峰. 14-3-3β和miR-152与肝细胞癌的相关性研究. 包头医学院学报. 2024(12): 18-23 .
2.	董勇，程序，梁晗，华静，谭莉霞，王航宇，闫春晓，魏书堂. 肝癌组织角蛋白23表达与患者临床病理特征及预后关系研究. 陕西医学杂志. 2023(06): 756-759 .
3.	张玉，高倩，邵建国，达坤林，陈宇锋，翁佳欣，陈琳. 季德胜蛇药治疗中晚期湿热瘀毒型肝癌患者的临床疗效观察及对患者血清miR-335的影响. 中国中西医结合消化杂志. 2022(06): 411-418 .
4.	许飞，李学军. 鳖甲煎丸在乙型肝炎肝硬化和肝癌中的作用机制及临床进展. 锦州医科大学学报. 2022(05): 108-112 .

Other cited types(0)

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article views (1306) PDF downloads (402) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Expression and Clinical Significance of miRNA-152 in Hepatocellular Carcinoma